Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial

Daiichi Sankyo (4568.T) and Merck (MRK.N) said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their disease progressing in a late-stage study.